Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Deciphera Pharmaceuticals reports robust Q4 performance and eyes market expansion

Deciphera Pharmaceuticals delivered strong financial results and outlined strategic priorities for future growth.
The company's focus on ctDNA analysis, market expansion, and potential label expansions position them well for continued success.
While facing uncertainties in guideline updates and market competition, Deciphera Pharmaceuticals remains optimistic about growth opportunities.

Deciphera Pharmaceuticals excels in Q1 2023, eyes international expansion

Deciphera Pharmaceuticals demonstrates strong financial performance and strategic achievements in Q1 2023, positioning the company for continued growth and market success.
While facing challenges from market dynamics and competition, the company's focus on international expansion, new drug development, and commercialization efforts presents promising opportunities.
By leveraging strengths in reimbursement ratings, clinical significance of key drugs, and pre-commercial activities, Deciphera is poised to capitalize on market opportunities and drive future growth.

Deciphera Pharmaceuticals excels in Q2, eyes international growth and innovation

Deciphera Pharmaceuticals delivered a standout performance in Q2 2023, driven by QINLOCK's robust revenue generation and international expansion.
While facing challenges such as high operating expenses and clinical trial complexities, the company remains focused on patient outcomes and program advancements.
Opportunities lie in continued revenue growth, clinical program progress, and leadership transitions, positioning Deciphera for future success and innovation.

Deciphera Pharmaceuticals excels in Q3 with record sales and innovative pipeline

Deciphera Pharmaceuticals shows strong financial and clinical performance in Q3 2023.
Balancing successful study outcomes with potential regulatory challenges and patient dynamics.
Company poised for significant revenue growth and market expansion with innovative products.
Continued focus on commercial success and pipeline advancement to drive future growth.

Deciphera Pharmaceuticals reports robust Q4 performance and eyes global expansion

Deciphera Pharmaceuticals showcased strong financial performance, clinical advancements, and strategic plans for growth in Q4 2023, positioning the company for continued success.
While facing challenges in market differentiation and operational execution, the company has opportunities for market expansion, record sales, and clinical development milestones in 2024.
Overall, Deciphera Pharmaceuticals' focus on QINLOCK sales, vimseltinib development, and international expansion underscores a comprehensive growth strategy and potential for market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States.

Deciphera Pharmaceuticals is the unusual case of a commercial-stage company whose drug succeeds at first but then has a major setback. Top-line data from a key phase 3 trial suggest that their flagship drug will not be moving from later-line to second-line therapy for GIST.

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the European Commission (EC) has approved QINLOCK® (ripretinib) in the European Union (EU) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib1. The

Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Unfavorable clinical results and a wide earnings miss will undoubtedly sink DCPH stock. Resist the temptation to buy the dip.

Take a Bearish Stance on Bruised and Battered Deciphera Pharmaceuticals

Today, investors in Deciphera Pharmaceuticals and DCPH stock have seen tremendous selling pressure take this stock to all-time lows. The post DCPH Stock Alert: Why Is Deciphera Pharmaceuticals Plunging 70%?

DCPH Stock Alert: Why Is Deciphera Pharmaceuticals Plunging 70%?

Shares of Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) tanked 75% on Friday morning after the U.S. firm said its INTRIGUE Phase III Clinical Study failed to meet the primary endpoint. The sharp decline wiped millions off its market cap that now stands at $565 million.

Deciphera Pharmaceuticals opened 75% down on Friday: explore why

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) stock plunged to a 52-week after announcing disappointing results from the INTRIGUE Phase 3 study of Qinlock in patients with gastrointestinal stromal tumor (GIST) previously treated with Novartis AG's (NYSE: NVS) Gleevec (imatinib).  The study did not meet the primary endpoint of improved progression-free survival (PFS) compared with the standard of care Pfizer Inc's (NYSE: PFE) Sutent (sunitinib).

Why Did Deciphera Stock Plunged 70% Today?

Why Did Deciphera Stock Plunge 70% Today?

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced top-line results from the INTRIGUE Phase 3 clinical study of QINLOCK in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib. The study did not meet the primary endpoint of improved progression-free survival (PFS) compared with the standard of care

Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study

Deciphera (DCPH) reports wider-than-expected loss and revenue miss in the third quarter. It is gearing up for multiple developments and pipeline updates in the fourth quarter.

Deciphera (DCPH) Q3 Loss Wider Than Expected, Revenues Miss

Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q3 2021 Results - Earnings Call Transcript

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -6.20% and -2.14%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Misses Revenue Estimates

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update. “In the third quarter, we made tremendous progress expanding the reach of QINLOCK for patients with GIST around the world. In addition to obtaining the approval for this important medicine in Switzerland and Taiwan, we also received a positive CHMP opinion for QINLOCK in the EU, with approval expected bef

Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its third quarter 2021 financial results on Tuesday, November 2, 2021. In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, November 2, 2021, to discuss the Company's financial results and provide a corporate update. The conference call may be accessed by dialing (866) 930-5479 (domestic) or (40

Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 2, 2021

Allakos Inc

BeyondSpring

These drugmakers have big events that should occur before the end of 2021.

3 Biotech Stocks With Huge Catalysts Incoming

Deciphera's (DCPH) Qinlock is approved for treating advanced gastrointestinal stromal tumors. The drug has seen solid uptake since its launch.

Deciphera (DCPH) Thrives on Qinlock, Overdependence a Woe

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for QINLOCK (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imati

Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced the presentation of preclinical data from the Company's first-in-class selective ULK kinase inhibitor, DCC-3116, in combination with EGFR inhibitors in non-small cell lung cancer (NSCLC) models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeu

Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Investors need to pay close attention to Deciphera (DCPH) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Deciphera (DCPH) Stock?

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced four e-poster presentations at the European Society for Medical Oncology (ESMO21) Virtual Conference 2021.  The presentations include updated preliminary results from the ongoing Phase 1b/2 study of rebastinib plus paclitaxel in Platinum-Resistant Ovarian Cancer (PROC) and vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT).

Deciphera Presents New Data Across Pipeline At ESMO Congress

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of QINLOCK (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have receiv

Deciphera Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced four e-poster presentations at the ESMO Congress 2021. The presentations include updated preliminary results from the ongoing Phase 1b/2 study of rebastinib in combination with paclitaxel in patients with PROC and updated preliminary results from the ongoing Phase 1/2 study of vim

Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that the Company will host a virtual investor event to review the rebastinib and vimseltinib clinical data to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2021 on Friday, September 17, 2021, from 10:00 AM to 12:30 PM ET. Deciphera's senior executive team will be joined by the following key opinion leaders at the event: Dr. Robert L. Coleman, M.D., FACOG, FACS, Gy

Deciphera Pharmaceuticals to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss Rebastinib and Vimseltinib Data Presented at ESMO Congress 2021

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?

Deciphera Pharmaceuticals, Inc. (DCPH) Down 0.8% Since Last Earnings Report: Can It Rebound?

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021 at 2:45 PM ET. The conference will be held in a virtual meeting format. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company's website at https://inve

Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference

Deciphera (DCPH) posts wider-than-expected loss in the second quarter due to rising R&D costs. Sales beat estimates on the encouraging uptake of Qinlock.

News for Deciphera Pharmaceuticals Stock (DCPH)